December 06, 2017
NASHVILLE, Tenn., Dec. 6, 2017 – Today, Sarah Cannon announced that 28 abstracts authored by members of the Sarah Cannon Blood Cancer Network have been selected by the American Society of Hematology (ASH) for presentation at the upcoming 2017 Annual Meeting & Exposition. Hosted in Atlanta, Ga. from December 9-12, the ASH Annual Meeting & Exposition is the world’s leading event in hematology research, bringing together more than 20,000 hematology and oncology professionals to discuss groundbreaking research in malignant and non-malignant blood cancer.
“We look forward to sharing our insights, including the latest developments in CAR T-cell therapy, from clinical trials across the Sarah Cannon Blood Cancer Network,” said Howard A. “Skip” Burris III, MD, President, Clinical Operations and Chief Medical Officer at Sarah Cannon. “CAR T-cell therapy continues to be an exciting advancement in the treatment of certain types of blood cancers, harnessing the body’s immune system to detect and fight cancer.”
Jesus Berdeja, MD, Director of Myeloma Research, Sarah Cannon Research Institute, will chair an oral session on myeloma therapy during which his co-authored abstract, “Durable Clinical Responses in Heavily Pre-Treated Patients with Relapsed/Refractory Multiple Myeloma: Updated Results from a Multicenter Study of bb2121 Anti-Bcma CAR T-Cell Therapy” will be presented. The presentation will take place on December 11 in the Georgia World Congress Center, Hall C1 from 2:45-4:15pm.
Other noteworthy studies include two oral presentations from Ian Flinn, MD, Director of Lymphoma Research, Sarah Cannon Research Institute, on safety and efficacy results from combination of venetoclax and obinutuzumab in patients with chronic lymphocytic leukemia (CLL), as well as Phase 3 results from the DUO™ trial comparing duvelisib and ofatumumab in patients with CLL or small lymphocytic lymphoma (SLL). Both presentations will take place on December 10 in the Georgia World Congress Center, Building B, Murphy 3-4.
The 28 abstracts represent studies being conducted by investigators from Sarah Cannon in affiliation with Colorado Blood Cancer Institute, Florida Cancer Specialists & Research Institute, Oklahoma University Medical Center, Tennessee Oncology, Texas Transplant Institute, and Tulane Medical Center.
“The Sarah Cannon Blood Cancer Network brings researchers and experts from across the U.S. and UK together to collaborate and determine the best treatment options for patients facing blood cancer,” said Fred LeMaistre, MD, Physician-in-Chief of Blood Cancers at Sarah Cannon. “Together, we are redefining cancer care through a commitment to clinical excellence and innovative research.”
The Sarah Cannon Blood Cancer Network is one of the largest providers of hematopoietic cell transplantation (HCT). It conducts more than 1,000 transplants annually through seven FACT accredited transplant centers, and has completed over 14,000 transplants since the inception of its first program.
About The Sarah Cannon Blood Cancer Network
Sarah Cannon brings together physician-led blood cancer programs across the United States and United Kingdom to offer patients convenient access to care including hematopoietic cell transplantation (HCT) and clinical trials. The Sarah Cannon Blood Cancer Network programs include St. David’s South Austin Medical Center in Austin, TX, Medical City Dallas Hospital in Dallas, TX, Colorado Blood Cancer Institute at Presbyterian/St. Luke’s Medical Center- HealthONE in Denver, Colo., HCA Midwest Health- Research Medical Center, in Kansas City, Mo., Sarah Cannon Center for Blood Cancer at TriStar Centennial Medical Center in Nashville, Tenn., Tulane Medical Center in New Orleans, La., OU Medical Center in Oklahoma City, Okla., Texas Transplant Institute at Methodist Hospital in San Antonio, TX, Harley Street at UCH in London and The Christie Clinic in Manchester, England. For more information about the Network and Sarah Cannon’s full suite of oncology services, visit sarahcannon.com.